-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target

Benzinga·07/27/2026 10:23:45
Listen to the news
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.